Bolt Biotherapeutics (BOLT) Consolidated Net Income (2020 - 2026)

Bolt Biotherapeutics has reported Consolidated Net Income for 7 years, with the latest figure at -$8.6 million in Q1 2026.

• Quarterly Consolidated Net Income rose 29.71% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (down 41.02% YoY) and the FY2025 annual result came in at -$137.2 million, up 19.22% from the prior year.
• Consolidated Net Income fell to -$8.6 million in Q1 2026 per BOLT's latest filing, from -$8.6 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$8.6 million in Q4 2025 and troughed at -$58.2 million in Q2 2022.
• A 5-year average of -$30.3 million and a median of -$21.5 million in 2022 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income surged 66.69% in 2024, then plunged 140.89% in 2025.
• Over 5 years, Consolidated Net Income stood at -$21.5 million in 2022, then soared by 44.92% to -$11.8 million in 2023, then slumped by 73.61% to -$20.6 million in 2024, then jumped by 58.32% to -$8.6 million in 2025, then fell by 0.93% to -$8.6 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$8.6 million, -$8.6 million, and -$40.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.